BB Healthcare Trust PLC Issue of Equity (0934Q)

TIDMBBH

RNS Number : 0934Q

BB Healthcare Trust PLC

23 February 2021

 
 
 
 23 February 2021 
 
 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, 
  TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH 
  AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE 
  OF DOUBT, THIS DOES NOT INCLUDE THE UK) OR TO ANY NATIONAL, 
  RESIDENT OR CITIZEN OF AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH 
  AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE 
  OF DOUBT, THIS DOES NOT INCLUDE THE UK) 
 
                        BB Healthcare Trust plc 
 
                        Issue of Ordinary Shares 
 
 BB Healthcare Trust plc (the "Company") announces that it has 
  today issued 361,000 of its ordinary shares of one penny each 
  ("Ordinary Shares") pursuant to its block listing facility. 
  The Ordinary Shares will be issued at a price of 185.72 pence 
  per Ordinary Share, a premium to the prevailing net asset value 
  ("cum income") per Ordinary Share. 
 
 Following the issue of Ordinary Shares, the Company's issued 
  share capital will comprise (506,295,455) Ordinary Shares and 
  this is the total number of Ordinary Shares with voting rights 
  in the Company. This figure (506,295,455) may be used by shareholders 
  as the denominator for the calculations by which they will determine 
  if they are required to notify their interest in, or a change 
  to, their interest in the Company under the Financial Conduct 
  Authority's Disclosure Guidance and Transparency Rules. 
 
 The Company's LEI is: 213800HQ3J3H9YF2UI82 
 
 For further information please contact: 
 
  Bellevue Asset Management (UK) Ltd. 
  Mark Ghahramani 
  Telephone: [phone] 
 
  J.P. Morgan Cazenove 
  James Bouverat (Sales) 
  Telephone: [phone] 
 
  Alvarium Securities Limited 
  Mark Thompson [phone] 
  Eddie Nissen [phone] 
  Oliver Kenyon [phone] 
 
 
 
 Disclaimer 
 
 This announcement does not constitute a prospectus relating 
  to the Company and does not constitute, or form part of, any 
  offer or invitation to sell or issue, or any solicitation of 
  any offer to purchase or subscribe for, any shares in the Company 
  in any jurisdiction nor shall it, or any part of it, or the 
  fact of its distribution, form the basis of, or be relied on 
  in connection with or act as any inducement to enter into, any 
  contract therefore. 
 
  J.P. Morgan Cazenove and Alvarium Securities Limited, which 
   are authorised and regulated by the Financial Conduct Authority, 
   are acting for the Company only in connection with the matters 
   described in this announcement and are not acting for or advising 
   any other person, or treating any other person as their client, 
   in relation thereto and will not be responsible for providing 
   the regulatory protection afforded to clients of Alvarium Securities 
   Limited and J.P. Morgan Cazenove or advice to any other person 
   in relation to the matters contained herein. 
 
 The shares of the Company have not been and will not be registered 
  under the US Securities Act of 1933, and may not be offered 
  or sold in the United States absent registration or an applicable 
  exemption from the registration requirements. Moreover, the 
  shares of the Company have not been, nor will they be, registered 
  under the applicable securities laws of Australia, Canada, the 
  Republic of South Africa, Japan or any member state of the EEA 
  (other than the United Kingdom). Further, the Company will not 
  be registered under the US Investment Company Act of 1940, as 
  amended. Subject to certain exceptions, the shares of the Company 
  may not be offered or sold in the United States, Australia, 
  Canada, the Republic of South Africa, Japan or any member state 
  of the EEA (other than the United Kingdom or to professional 
  investors in Ireland) or to, or for the account or benefit of, 
  any national, resident or citizen of the United States, Australia, 
  Canada, the Republic of South Africa, Japan or any member state 
  of the EEA (other than the United Kingdom or to professional 
  investors in Ireland). The share issuance programme, and the 
  distribution of this announcement, in other jurisdictions may 
  be restricted by law and the persons into whose possession this 
  announcement comes should inform themselves about, and observe, 
  any such restrictions. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFLFFRFTIVFIL

(END) Dow Jones Newswires

February 23, 2021 11:28 ET (16:28 GMT)